Cyclophos Special Precautions

Since Cyclophosphamide is a cytotoxic anticancer drug, procedures for proper handling and disposal of such drug should be followed.
Myelosuppression is frequently encountered with Cyclophosphamide; hematologic profile especially neutrophils and platelets should be monitored regularly to determine the degree of hematopoietic suppression.
The urinary sediment should be monitored regularly for red blood cells which may proceed to hemorrhagic cystitis. To prevent toxicity of urinary bladder, large quantities of fluid should be taken during or immediately after administration of Cyclophosphamide.
Prior to initiation of therapy, all conditions of hampered urinary flow in the efferent urinary passages should be excluded and disturbance of electrolyte balance should be corrected.
Patients of both sexes of reproductive age should take contraceptive measures throughout treatment with Cyclophosphamide and for at least six months after its termination so as to preclude any risk of conception.
Patients with impaired renal and hepatic function must be monitored carefully. In cases of patients with severe renal impairment, Cyclophosphamide dosage and reduction may be required.
Patients should be advised to maintain oral and dental hygiene to prevent infections.
Effects on ability to drive and use machines: Patients undergoing treatment with Cyclophosphamide may experience undesirable effects (including nausea, vomiting, dizziness, blurred vision, visual impairment) which could affect the ability to drive or use machines. The decision to drive or operate machinery should be made on an individual basis.